

Substitute for Form PTO-1595

# RECORDATION FORM COVER SHEET PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office

Attorney's Docket No. 1020600-000279

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copy thereof.


<p>1. Name of conveying party(ies):</p> <p>Zxillion GmbH &amp; Co. KG</p> <p>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and address of receiving party(ies):</p> <p>Name: Proteome Sciences R&amp;D GmbH &amp; Co. KG</p> <p>Address: Altenhoferallee 3 D-60438 Frankfurt am Main GERMANY</p> <p>Additional name(s) &amp; addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>3. Nature of conveyance:</p> <p><input checked="" type="checkbox"/> Assignment      <input type="checkbox"/> Merger</p> <p><input type="checkbox"/> Security Agreement      <input type="checkbox"/> Change of Name</p> <p><input type="checkbox"/> Other</p> <p>Execution Date: 06/29/2005</p>	

4. Application number(s) or patent number(s):  
If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

<p>A. Patent Application No.(s)</p> <p>10/479,843 10/479,855 10/479,868</p>	<p>B. Patent No.(s)</p> <p>6,156,527</p> <p>Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
---	--

<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>Name: Teresa Stanek Rea</p> <p>Address: Buchanan Ingersoll PC Including attorneys from Burns, Doane, Swecker &amp; Mathis Customer Number 2 1 8 3 9 P.O. Box 1404 Alexandria, VA 22313-1404</p>	<p>6. Total number of applications and patents involved: <input type="text" value="4"/></p> <p>7. Total fee (37 CFR 3.41).....\$ 40.00 (8021)</p> <p><input type="checkbox"/> Enclosed</p> <p><input checked="" type="checkbox"/> Authorized to be charged to deposit account</p> <p><input type="checkbox"/> Credit card. Form PTO-2038 is attached.</p> <p>8. Deposit account number: 02-4800 (Attach duplicate copy of this page if paying by deposit account.)</p>
---	--

9. Statement and Signature.  
*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

<p>Teresa Stanek Rea</p> <p>Name of Person Signing</p>	<p>30,427</p> <p>Reg. No.</p>	 <p>Signature</p>	<p>3/6/06</p> <p>Date</p>
<p>Total number of pages including cover sheet, attachments, and documents: <input type="text" value="17"/></p>			

Mail documents to be recorded with required cover sheet information to:  
Director of the United States Patent and Trademark Office / Mail Stop Assignment Recordation Services  
P.O. Box 1450 / Alexandria, VA 22313-1450

CH \$160.00 024800 10479843

## Confirmatory Assignment

**DATE:** June 29, 2005

### PARTIES:

1. **AVENTIS PHARMA DEUTSCHLAND GmbH** a limited liability company with registered number HRB 40661 and its registered office located at Industriepark Höchst, D65926 Frankfurt am Main ("Aventis Pharma"); and
2. **PROTEOME SCIENCES R&D GMBH & CO KG** (formerly known as Xzillion GmbH & Co. KG itself formerly known as Xzillion Proteomics GmbH & Co. KG) a limited partnership formed in Germany by a partnership agreement dated 21 March 2002 with registered number HRA 30493 and its registered office located at Altenhöferallee 3, D-60438 Frankfurt am Main ("Proteome").

### RECITALS:

1. Xzillion GmbH & Co. KG (registered number HRA 29798) was a limited partnership established by Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) as its sole limited partner and Xzillion Verwaltungs GmbH (then with its registered office in Frankfurt am Main, registered number HRB 46580) as its sole general partner.
2. Proteome was established on 21 March 2002 under the firm name Xzillion Proteomics GmbH & Co. KG (registered number HRA 30493) by its sole limited partner Xzillion GmbH & Co. KG (registered number HRA 29798) and its sole general partner Xzillion Proteomics Verwaltungs GmbH (registered number HRB 52072). Following formation of Proteome, Xzillion GmbH & Co. KG (registered number HRA 29798) transferred certain assets (including the Intellectual Property (as defined below)) to Proteome (then called Xzillion Proteomics GmbH & Co. KG (registered number HRA 30493)) by an agreement dated 27 March 2002 (the "Contribution Agreement").
3. Immediately following the transfer of assets by Xzillion GmbH & Co. KG (registered number HRA 29798) to Proteome, Xzillion Verwaltungs GmbH (registered number HRB 46580) withdrew from the partnership Xzillion GmbH & Co. KG (registered number HRA 29798) and all of the assets and obligations of Xzillion GmbH & Co. KG (registered number HRA 29798) were transferred by operation of law to Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) as the sole limited partner of Xzillion GmbH & Co. KG (registered number HRA 29798). Aventis

- Research and Technologies GmbH & Co KG (registered number HRA 28517) became the legal successor to Xzillion GmbH & Co. KG (registered number HRA 29798).
4. Proteome Sciences plc acquired the sole limited partnership interest in Proteome as well as all shares in Proteome's sole general partner Xzillion Proteomics Verwaltungs GmbH (with its registered office in Frankfurt am Main, registered number HRB 52072) pursuant to a notarial sale and purchase agreement between Proteome Sciences plc and Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) dated 4 July 2002, deed No. 200/2002 of notary Dr. Günther Philipps, Frankfurt am Main (the "Sale and Purchase Agreement"). Proteome owned various intellectual property rights that were contributed by the Contribution Agreement including the Intellectual Property (as defined below). The Sale and Purchase Agreement provides in its clause 20 (1) that Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) shall procure the due assignment of such Intellectual Property (as defined below).
  5. On or before 19 September 2002 Proteome changed its name to Xzillion GmbH & Co. KG (registered number HRA 30493).
  6. With legal effect as of 31 May 2003 and registered with the commercial register on 18 June 2003 Hoechst AG, as sole limited partner in Aventis Research & Technologies GmbH & Co KG withdrew from the limited partnership leading to the dissolution of the partnership Aventis Research & Technologies GmbH & Co KG. All of its assets and obligations were transferred by operation of law to the sole general partner Aventis Research & Technologies Verwaltungs GmbH (registered number HRB 39459), which became the legal successor of the limited partnership.
  7. With effect as of registration on 29 August 2003, Aventis Research & Technologies Verwaltungs GmbH (registered number HRB 39459) was merged into Aventis Pharma as the transferee company with Aventis Pharma becoming the legal successor to Aventis Research & Technologies Verwaltungs GmbH (registered number HRB 39459) and due to the previous transfer of assets and obligations under para. 6 above accordingly the final legal successor to Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) and to all of the assets and obligations of Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) and Aventis Pharma assuming by operation of law the obligations of Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) in respect of the Intellectual Property (as defined below).
  8. On 14<sup>th</sup> November 2003 and registered with the commercial register on 2 February 2004 Xzillion GmbH & Co. KG (HRA 30493) changed its name to Proteome Sciences R&D GmbH & Co KG, retaining HRA 30493 as its company number.
  9. The purpose of this Confirmatory Assignment is to confirm the assignment of Intellectual Property made under the Contribution Agreement and for Aventis

Pharma to confirm the assignment to Proteome Sciences R&D GmbH & Co KG (registered number 30493) of any and all right, title or interest it has in any of the Intellectual Property (as defined below).

## OPERATIVE PROVISIONS:

### 1 Confirmatory Assignment

1.1 In accordance with its obligation under the Contribution Agreement, Aventis Pharma hereby;

1.1.1 confirms the assignment of Intellectual Property made under the Contribution Agreement; and, for the avoidance of doubt,

1.1.2 assigns in fulfilment of the obligation entered into in the Contribution Agreement with full title guarantee to Proteome – in accordance with Section 413 in connection with Sections 398 et seqq. of the German Civil Code – absolutely:

- (a) all its rights, title and interest in and to the patents and patent applications identified in the Schedule to this Confirmatory Assignment throughout the world (“the Intellectual Property”);
- (b) all rights and powers arising or accrued from such Intellectual Property including the right to sue for damages and other remedies and to have the benefit of any remedy obtained on any supposed infringement of such Intellectual Property before the date of this Confirmatory Assignment; and
- (c) the rights to apply for protection in any part of the world in relation to all or any part of the Intellectual Property including the right to apply for renewals and extensions and the right to claim priority from earlier applications.

1.2 Proteome accepts the assignment of the Intellectual Property.

### 2 Further Assurance

2.1 Aventis Pharma represents and warrants to Proteome that;

- (a) the information set out in recitals 1, 2, 3, 6 and 7 is correct;
- (b) that as far as its operation (*Geschäftsbereich*) Aventis Research & Technologies is aware no claims have been notified to it challenging or threatening to challenge the use, validity or ownership of the Intellectual Property;

- (c) as far as its operation (*Geschäftsbereich*) Aventis Research & Technologies is aware, all application, renewal and other official registry fees have been paid.
- (d) Xzillion GmbH & Co. KG (registered number HRA 29798), Aventis Research & Technologies GmbH & Co KG (registered number (HRA 28517) and Aventis Pharma have not transferred the Intellectual Property to any third party other than to Proteome.

The assurances in lit. (a) through (d) above shall not constitute warranties for character (*Beschaffheitsgarantie*) within the meaning of Section 443 para. 1 and Section 444 of the German Civil Code, but independent guarantee agreements in the meaning of Sections 311 para. 1, 276 para.1 sentence 1 of the German Civil Code. Except for the accuracy of the assurances in lit. (a) through (d) above, no further assurances are granted. Awareness of Aventis Pharma in lit. (b) and (c) above shall expressly be limited to awareness of the operation (*Geschäftsbereich*) of Aventis Research & Technologies within Aventis Pharma (the former Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517)) and shall expressly exclude all other divisions and operations of Aventis Pharma. The operation (*Geschäftsbereich*) Aventis Research & Technologies is the division within Aventis Pharma which handled and handles the winding off, transfer and transformation of the business activities of Aventis Research & Technologies GmbH & Co KG (registered number HRA 28517) and its former subsidiary Xzillion GmbH & Co. KG (registered number HRA 29798) including the transfer of assets to Proteome. With respect to the assurances in lit. (b) to (d) above Proteome acknowledges that since the execution of the Sale and Purchase Agreement the administration of the Intellectual Property has been handled by the patent attorneys Page White & Farrer and/or Dr. Ackermann respectively on behalf of Proteome.

- 2.2 Aventis Pharma hereby covenants with Proteome that it will, at its own expense, execute or sign all such instruments, applications and documents and do all things as may reasonably be required by Proteome (or the nominee of Proteome) to acquire the legal and equitable title to the Intellectual Property and to enjoy the full benefit of the property and rights hereby assigned and (if requested to do so by Proteome), apply for any patents or other forms of protection and fully and effectually vest the same in Proteome, or as Proteome shall direct.

### 3. General

- 3.1 Failure by either party to enforce at any time or for any period any one or more of the terms or conditions of this Confirmatory Assignment shall not be a waiver of them or the rights at any time subsequently to enforce all terms and conditions of this Confirmatory Assignment. Nothing in this Confirmatory Assignment shall result in any loss or reduction of Proteome's rights under the Contribution Agreement.

- 3.2 In the case that one or more provisions of this Agreement shall be invalid or unenforceable, this shall not affect the validity and enforceability of the other provisions of this Agreement. In such case the Parties agree to recognize and give effect to such valid and enforceable provision or provisions which reflect as closely as possible the commercial intention of the Parties associated with the invalid or unenforceable provision. The same shall apply in the event that the Agreement contains any omissions (*Vertragslücken*).
- 3.3 The obligations contained in this Confirmatory Assignment which have not been performed at completion of this Confirmatory Assignment shall survive completion. Proteome shall be free to assign the rights granted hereunder without approval of Aventis Pharma provided that Aventis Pharma is notified of such assignment in writing.
- 3.4 This Confirmatory Assignment shall be binding on and for the benefit of each party's successors and personal representatives.
- 3.5 This Confirmatory Assignment is governed by and construed in accordance with the laws of the Federal Republic of Germany, and the parties agree to submit to the exclusive jurisdiction of the courts of Frankfurt am Main to settle any claim, dispute or matter of difference which may arise in connection with this Confirmatory Assignment.

IN WITNESS whereof the parties hereto have hereunto set their respective hands.

For and on behalf of  
**AVENTIS PHARMA DEUTSCHLAND GmbH**  
Signed by:

Name: ppa. Jürgen Blicke  
Title: "Prokurist" - Authorized Signatory  
Date: 29.06.2005

ppa. Manuel Klauf  
ppa. Manuel Klauf  
"Prokurist" - Authorized Signatory  
29.06.2005

Signed by: CD Pearce  
For and on behalf of  
**PROTEOME SCIENCES R&D GMBH & CO KG**  
By its sole general partner  
**PROTEOME SCIENCES R&D VERWALTUNGS GmbH**

Name: CD J PEARCE  
Title: Managing Director  
Date: 30<sup>th</sup> June 2005

**SCHEDULE**

**PAGE WHITE & FARRER CASES**

Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>Protein Profiling 1 (PST 1)</b>									
83471*	GB 9701357.7	23-Jan-97	Characterising Polypeptides	GB					Abandoned
85956*	GB 9726947.6	19-Dec-97	Characterising Polypeptides	GB	WO98/32876	30-Jul-98			Abandoned
86360	PCT/GB98/00201	23-Jan-98	Characterising Polypeptides	PCT	2001-508872	03-Jul-01			Clone National
92454	JP 10-531728	23-Jan-98	Characterising Polypeptides	JP	WO98/32876	30-Jul-98	AU 721 390	12-Oct-00	Pending
92452	AU 56745/98	23-Jan-98	Characterising Polypeptides	AU	WO98/32876	30-Jul-98	NZ 336768	04-Apr-02	Granted
92450	NZ336768	23-Jan-98	Characterising Polypeptides	NZ	WO98/32876	30-Jul-98	IL 130949		Granted
92449	IL 130949	23-Jan-98	Characterising Polypeptides	IL	WO98/32876	30-Jul-98	EP 1027454	13-Aug-03	Granted
92447	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	CN 1118580	20-Aug-03	Granted
92448	CN 98801977.9	23-Jan-98	Characterising Polypeptides	CN	CN 1244218A	09-Feb-00	CA 2278556	29-Jul-03	Granted
92451	CA2278556	23-Jan-98	Characterising Polypeptides	CA	WO98/32876	30-Jul-98	US 6156527	05-Dec-00	Granted
92453	US 09/341993	23-Jan-98	Characterising Polypeptides	US	WO98/32876	30-Jul-98			Allow to lapse
201773	HK 01101099.7	23-Jan-98	Characterising Polypeptides	HK	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209685	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209686	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209687	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209688	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209689	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209690	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209691	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209692	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209693	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209694	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209695	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted
209696	EP 98900949.3	23-Jan-98	Characterising Polypeptides	EP	EP 1027454	16-Aug-00	EP 1027454	13-Aug-03	Granted



Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>Protein Profiling 2 (PST 2)</b>									
88809*	GB 9821393.7	1-Oct-98	Characterising Polypeptides through Cleavage and Mass Spectrometry	GB	Never Published				Abandoned
100280	PCT/GB99/03258	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	PCT	WO 00/20870	13-Apr-00			Gene National
202381	NO 200115522	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	NO	WO 00/20870	13-Apr-00			Pending
202386	IL 142314	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	IL	WO 00/20870	13-Apr-00			Pending
202384	CA2344642	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	CA	WO 00/20870	13-Apr-00	CA 2344642	22-Jun-04	Granted
202385	NZ 510873	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	NZ	WO 00/20870	13-Apr-00			Pending
202379	AU 61096/99	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	AU	WO 00/20870	13-Apr-00	AU 768902	29-Apr-04	Granted
202380	EP99947722.7	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	EP	EP 1117999 A	25-Jul-01	EP 1117999 B	05-Feb-03	Granted
202382	US 09/806564	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	US	WO 00/20870	19-Apr-00			Allowed
202383	JP 574937/2000	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	JP	JP 2002-526778	20-Aug-02			Pending
202387	CN 99812504.0	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	CN	WO 00/20870	13-Apr-00	EP 1117999 (UK)	05-Feb-03	To be abandoned
208258	EP 1117999 (UK)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	UK	EP 1117999 (UK)	25-Jul-01	EP 1117999 (FI)		Granted
208256	EP 1117999 (FI)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	FI	EP 1117999 (FI)	25-Jul-01	EP 1117999 (AT)		Granted
208249	EP 1117999 (AT)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	AT	EP 1117999 (AT)	25-Jul-01	EP 1117999 (BE)		Granted
208250	EP 1117999 (BE)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	BE	EP 1117999 (BE)	25-Jul-01		05-Feb-03	Granted

Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>Protein Profiling 2 (PST 2) continued</b>									
208251	EP 1117999 (CH)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	CH	EP 1117999 (CH)	25-Jul-01	EP 1117999 (CH)	05-Feb-03	Granted
208252	EP 1117999 (CY)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	CY	EP 1117999 (CY)	25-Jul-01	EP 1117999 (CY)	05-Feb-03	Granted
208253	EP 1117999 (DE)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	DE	EP 1117999 (DE)	25-Jul-01	EP 1117999 (DE)	05-Feb-03	Granted
208254	EP 1117999 (DK)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	DK	EP 1117999 (DK)	25-Jul-01	EP 1117999 (DK)	05-Feb-03	Granted
208255	EP 1117999 (ES)	1-Oct-99	Characterising Polypeptides through Cleavage and Mass Spectrometry	ES	EP 1117999 (ES)	25-Jul-01	EP 1117999 (ES)	05-Feb-03	Granted
<b>N-term PST with hindered sulphones (PST 3)</b>									
203868*	EP 01304975.4	7-Jun-01	Characterising Polypeptides	EP	Never Published				Abandoned
208152	PCT/GB02/02601	7-Jun-02	Characterising Polypeptides	PCT	WO 02/099124	12-Dec-02			Granted National
210290	2003 5369	7-Jun-02	Characterising Polypeptides	NO	WO 02/099124	12-Dec-02			Pending
210291	10479855	7-Jun-02	Characterising Polypeptides	US	WO 02/099124	12-Dec-02			Pending
210292	2003-502233	7-Jun-02	Characterising Polypeptides	JP	WO 02/099124	12-Dec-02			Pending
210293	2002310610	7-Jun-02	Characterising Polypeptides	AU	WO 02/099124	12-Dec-02			Pending
210294	2449942	7-Jun-02	Characterising Polypeptides	CA	WO 02/099124	12-Dec-02			Pending
210295	529987	7-Jun-02	Characterising Polypeptides	NZ	WO 02/099124	12-Dec-02			Pending
210296	EP 02735600.5	7-Jun-02	Characterising Polypeptides	EP	WO 02/099124	12-Dec-02			Pending

Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>C-term PST's with hindered sulphones (PST 4)</b>									
204703*	EP 01306842.4	10-Aug-01	Characterising Polypeptides	EP	EP 1265072 A1	11-Dec-02			Abandoned
208153	PCT/GB02/02778	7-Jun-02	Characterising Polypeptides	PCT	WO 02/099436	12-Dec-02			Gone National
210257	EP 02730519.2	7-Jun-02	Characterising Polypeptides	EP	WO 02/099436	12-Dec-02			Pending
210258	2002302837	7-Jun-02	Characterising Polypeptides	AU	WO 02/099436	12-Dec-02			Pending
210259	2449681	7-Jun-02	Characterising Polypeptides	CA	WO 02/099436	12-Dec-02			Pending
210260	529986	7-Jun-02	Characterising Polypeptides	NZ	WO 02/099436	12-Dec-02			Pending
210261	2003 5370	7-Jun-02	Characterising Polypeptides	NO	WO 02/099436	12-Dec-02			Pending
210262	10479868	7-Jun-02	Characterising Polypeptides	US	WO 02/099436	12-Dec-02			Pending
210263	2003-502505	7-Jun-02	Characterising Polypeptides	JP	WO 02/099436	12-Dec-02			Pending
<b>Peptide Mass Fingerprinting with Labels (Sensitiser) (SMT 1)</b>									
206375*	EP02250740.4	4-Feb-02	Method for Characterising Polypeptides	EP	EP 1265072 A1	11-Dec-02			Abandoned
208154	PCT/GB02/02605	7-Jun-02	Method for Characterising Polypeptides	PCT	WO 02/099435	12-Dec-02			Gone National
210250	EP 02735602.1	7-Jun-02	Method for Characterising Polypeptides	EP	WO 02/099435	12-Dec-02			Pending
210251	2002310611	7-Jun-02	Method for Characterising Polypeptides	AU	WO 02/099435	12-Dec-02			Pending
210252	2449680	7-Jun-02	Method for Characterising Polypeptides	CA	WO 02/099435	12-Dec-02			Pending
210253	529985	7-Jun-02	Method for Characterising Polypeptides	NZ	WO 02/099435	12-Dec-02			Pending
210254	2003 5402	7-Jun-02	Method for Characterising Polypeptides	NO	WO 02/099435	12-Dec-02			Pending
210255	10479843	7-Jun-02	Method for Characterising Polypeptides	US	WO 02/099435	12-Dec-02			Pending
210256	2003-502504	7-Jun-02	Method for Characterising Polypeptides	JP	WO 02/099435	12-Dec-02			Pending

Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>Tandem Mass Tags (TMT 1)</b>									
89324	GB 9826159.7	27-Nov-98	Use of MS/MS to selectively acquire mass markers	GB	Never published				Terminated 15-Feb-00
91736*	GB 0006141.6	14-Mar-00	Mass Labels	GB	Never published				Abandoned
100765	PCT/GB01/01122	8-Mar-01	Mass Labels	PCT	WO 01/68664	20-Sep-01			Gene National
208632	AU 240834/01	8-Mar-01	Mass Labels	AU	WO 01/68664	20-Sep-01		29-Mar-04	Granted
208633	NZ 521527	8-Mar-01	Mass Labels	NZ	WO 01/68664	20-Sep-01	NZ 521 527		Pending
208629	EP 01911912.2	8-Mar-01	Mass Labels	EP	WO 01/68664	20-Sep-01			Pending
208635	IL 151732	8-Mar-01	Mass Labels	IL	WO 01/68664	20-Sep-01			Pending
208634	CA 2403114	8-Mar-01	Mass Labels	CA	WO 01/68664	20-Sep-01			Pending
208636	CN 01809041.9	8-Mar-01	Mass Labels	CN	CN 1427953A	02-Jul-03			Pending
208640	NO 2002 4344	8-Mar-01	Mass Labels	NO	WO 01/68664	20-Sep-01			Pending
208630	US 10/221866	8-Mar-01	Mass Labels	US	WO 01/68664	20-Sep-01			Pending
208631	JP 567754/2001	8-Mar-01	Mass Labels	JP	WO 01/68664	20-Sep-01			Pending
<b>Peptide Tandem Mass Tags (TMT 2)</b>									
202375*	EP 01307830.8	14-Sep-01	Mass Labels	EP	Never published				Abandoned
208649	PCT/GB02/04240	16-Sep-02	Mass Labels	PCT	WO 03/025576	27-Mar-03			Pending
210633	US 10/489,341	16-Sep-02	Mass Labels	US	WO 03/025576	27-Mar-03			Pending
210634	2003-529154	16-Sep-02	Mass Labels	JP	WO 03/025576	27-Mar-03			Pending
210635	CA 2469131	16-Sep-02	Mass Labels	CA	WO 03/025576	27-Mar-03			Pending
210636	2002 331952	16-Sep-02	Mass Labels	AU	WO 03/025576	27-Mar-03			Pending
210637	EP 02767650.1	16-Sep-02	Mass Labels	EP	WO 03/025576	27-Mar-03			Pending

## DR. ACKERMANN CASES

Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>DNA Binding Peptides</b>									
200at10.de	10041126.6	22/8/2000	DNA Binding Peptide Domains and a Method for Providing Domains of this Type	Germany (Priority)	Never Published				Abandoned
200at10.wo	PCT/EP01/09565	20/8/2001	DNA Binding Peptide Domains and a Method for Providing Domains of this Type	International	WO02/16424A2	28/02/2002			Abandoned
200at10.us	10/344620	20/8/2001	DNA Binding Peptide Domains and a Method for Providing Domains of this Type	USA	US-2004-0072189-A1				Abandoned
200at10.au	2001291774	20/8/2001	DNA Binding Peptide Domains and a Method for Providing Domains of this Type	Australia	WO02/16424A2	28/02/2002			Abandoned
200at10.ep	01971927.7-1212	20/8/2001	DNA Binding Peptide Domains and a Method for Providing Domains of this Type	Europe	WO02/16424A2	28/02/2002			Abandoned
200at10.ca	2420251	20/8/2001	DNA Binding Peptide Domains and a Method for Providing Domains of this Type	Canada	WO02/16424A2	28/02/2002			Abandoned
<b>Protein Conjugates</b>									
199at18.de	19957916.4	01/12/1999	New Protein Conjugates And Method For Their Manufacture	Germany (Priority)	Never Published				Abandoned
199at18.ca	2327140	30/11/2000	New Protein Conjugates And Method For Their Manufacture	Canada					Abandoned
199at18.us	09723556	28/11/2000	New Protein Conjugates And Method For Their Manufacture	USA					Abandoned
199at18.ep	00122132.4	12/10/2000	New Protein Conjugates And Method For Their Manufacture	Europe	EP 1104677	06/06/2001			Abandoned
199at18.jp	2000-367310	01/12/2000	New Protein Conjugates And Method For Their Manufacture	Japan					Pending

Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>Electrophoretic Separation</b>									
201xz01.de	101.27406.8	6/6/2001	Method for Electrophoretic Sample Separation	Germany (Priority)	Never Published				Abandoned
201xz01.wo	PCT/EP02/03969	31/5/2002	Method for Electrophoretic Sample Separation	International	WO02/099404	12/12/2002			Abandoned
201xz01.us	10/479454	31/5/2002	Method for Electrophoretic Sample Separation	USA	WO02/099404	12/12/2002			Abandoned
201xz01.ep	027381334	31/5/2002	Method for Electrophoretic Sample Separation	Europe	WO02/099404	12/12/2002			Abandoned
<b>Proteoprep</b>									
197at18.de	19755960.3	16/12/1997	Method for Decomposing Biological Material	Germany (Priority)	Never Published				Granted
197at18.wo	PCT/EP98/07861	3/12/1998	Method for Decomposing Biological Material	International	WO99/31219	24/06/1999			Come National
197at18.ca	2313255	3/12/1998	Method for Decomposing Biological Material	Canada	WO99/31219	24/06/1999	734563		Abandoned
197at18.au	734563	3/12/1998	Method for Decomposing Biological Material	Australia	WO99/31219	24/06/1999			Granted
197at18.eu	99930902.4	3/12/1998	Method for Decomposing Biological Material	Europe	WO99/31219	24/06/1999			Abandoned
197at18.ep	PV2000-2261	3/12/1998	Method for Decomposing Biological Material	Czech Republic	WO99/31219	24/06/1999			Abandoned
197at18.cz	PCT/EP98/07861	3/12/1998	Method for Decomposing Biological Material	Hungary	WO99/31219	24/06/1999			Abandoned
197at18.jp	2000-539120	3/12/1998	Method for Decomposing Biological Material	Japan	WO99/31219	24/06/1999			Abandoned
197at18.no	20002878	3/12/1998	Method for Decomposing Biological Material	Norway	WO99/31219	24/06/1999			Abandoned
197at18.pl	342100	3/12/1998	Method for Decomposing Biological Material	Poland	WO99/31219	24/06/1999			Abandoned
197at18.us	09/581563	3/12/1998	Method for Decomposing Biological Material	USA	WO99/31219	24/06/1999			Granted

Agent Code	Application Number	Filing Date	Published Title	Country Code	Publication Number	Publication Date	Grant Number	Grant Date	Status
<b>Isoelectric Focusing of Modified Membrane Proteins</b>									
201xz02.de	10143346.8	4/9/2001	Method for Separating Macromolecules Having Been Chemically Modified in a Reversible Manner	Germany (Priority)	Never Published				Pending
201xz02.pet	PCT/EP02/09808	3/9/2002	Method for Separating Macromolecules Having Been Chemically Modified in a Reversible Manner	International	WO03/021274	13/03/2003			Goods National
201xz02.ca	2459231	3/9/2002	Method for Separating Macromolecules Having Been Chemically Modified in a Reversible Manner	Canada	WO03/021274	13/03/2003			Pending
201xz02.ep	02738133.4	3/9/2002	Method for Separating Macromolecules Having Been Chemically Modified in a Reversible Manner	Europe	WO03/021274	13/03/2003			Pending
201xz02.jp	2003525306	3/9/2002	Method for Separating Macromolecules Having Been Chemically Modified in a Reversible Manner	Japan	WO03/021274	13/03/2003			Pending
201xz02.au	2002361194	3/9/2002	Method for Separating Macromolecules Having Been Chemically Modified in a Reversible Manner	Australia	WO03/021274	13/03/2003			Pending
201xz02.us	10/487535	3/9/2002	Method for Separating Macromolecules Having Been Chemically Modified in a Reversible Manner	United States	US-2004-0248127-A1				Pending

No. 80 of the Roll of Deeds for 2005

I, the undersigned Dr. Oleg de Lousanoff, Notary in Frankfurt am Main (Federal Republic of Germany), hereby certify that Messrs.

**Jürgen Winfried BLIEKE**, date of birth: June 23, 1954,  
residing at: Erlenweg 32, 65835 Liederbach am Taunus (Germany),  
personally known to me,

und


**Manuel Krauß**, date of birth: 22 July, 1967,  
residing at: Erlenweg 15, 65835 Liederbach (Germany),  
personally known to me,

have subscribed the signatures on page 6 of the annexed document in my presence.

I further certify that the Commercial Register maintained by the local court in Frankfurt am Main -which I have inspected today- shows under docket number HR B 40661 the registration of Aventis Pharma Deutschland GmbH (the "Company"), and of Messrs. Jürgen Winfried Blicke and Manuel Krauß as "Procurists" of the company as authorized to represent said company by acting jointly.

The Notary has informed the persons appearing about the provision of Section 3, Subsection 1, No. 7 of the Recording Act (Beurkundungsgesetz). The persons appearing thereupon have stated that the Notary is not prevented from recording under such provision.

Frankfurt am Main, June 29, 2005



*Oleg de Lousanoff*  
de Lousanoff  
Notary

**Statement of Fees**

Value: over € 310.000,00

Fee pursuant to §§ 141, 32, 35 I KostO

€ 130,00

Fee pursuant to §§ 141, 32, 38 I KostO

€ 30,00

Fee pursuant to § 150 No. 1 KostO

€ 13,00

Flat fee for copies pursuant to §§ 141, 136 I No. 1, No. 2, II KostO

€ 2,00

Postage pursuant to § 152 II Nr. 1 a) KostO

€ 1,44

Subtotal

€ 176,44

VAT 16 % pursuant to § 151a KostO

€ 28,23

Total

€ 204,67

*Oleg de Lousanoff*  
Notary



TO ALL TO WHOM these presents shall come I IRENE TENNENT CRABB of Cobham in the County of Surrey in England Notary Public duly authorised admitted and sworn and practising within the United Kingdom of Great Britain and Northern Ireland DO HEREBY CERTIFY and attest that the signature "C. D. J. Pearce" set and subscribed at the foot of page 6 of the hereunto annexed document is genuine, the same having been duly subscribed thereto by CHRISTOPHER DONOVAN JAMES PEARCE who is personally known to me

**IRENE T. CRABB**

**Notary Public**

**Cedar House  
78 Portsmouth Road  
Cobham  
Surrey  
KT11 1AN  
England**

**IN TESTIMONY** whereof I have hereunto subscribed my name and affixed my Seal of Office at Cobham in the County of Surrey in England aforesaid this 30th day of June 2005

**Fax +44 (0) 1932 590220**

**Telephone No. +44 (0) 1932 590500**

**Authority unlimited**

**Notary Public**

IRENE T. CRABB  
Notary Public  
Cedar House  
78 Portsmouth Road  
Cobham Surrey  
KT11 1AN England  
Tel: +44 (0)1932 590500  
Fax: +44 (0)1932 590220  
E-Mail: irene@irenet.co.uk

